Mansouri Shahla, Kalantar Davood, Asadollahi Parisa, Taherikalani Morovat, Emaneini Mohammad
Department of Microbiology, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Roum Arch Microbiol Immunol. 2012 Apr-Jun;71(2):81-6.
Klebsiella pneumoniae is a major cause of nosocomial infections. Emergence of antibacterial resistance and production of beta-lactamases are responsible for the frequently observed empirical therapy failures. The aim of this study was to determine the presence and the prevalence of extended spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases in clinical isolates of K. pneumoniae in Kerman, Iran. Resistance to different antibiotics was determined using standard disk diffusion method. The beta-lactamases phenotypes were determined by combined disk method. Polymerase chain reaction (PCR) was used to determine blaCTX-M and blaCMY genes in the ESBLs and AmpC positive isolates. Out of the 75 K. pneumoniae isolates, 31 (41.3%) produced ESBLs, 11 (14.6%) produced AmpC beta-lactamases and 1 (1.3%) was resistant to imipenem, probably by the production of a metallo beta lactamase in the phenotypic assay. Simultaneous production of ESBLs and AmpC beta-lactamases as well as the concomitant presence of blaCTX-M and blacMY genes was detected in one isolate. Prevalence of blaCTX-M and blaCMY among isolates were 20% and 2.6%, respectively. Beta-lactam therapy can fail when beta-lactamase-hyper-producing organisms appear in an infection. The occurrence of isolates co-expressing many types of beta-lactamases can cause serious problems, regarding the treatment of infections caused by these pathogens.
肺炎克雷伯菌是医院感染的主要原因。抗菌药物耐药性的出现和β-内酰胺酶的产生是导致常见经验性治疗失败的原因。本研究的目的是确定伊朗克尔曼地区肺炎克雷伯菌临床分离株中广谱β-内酰胺酶(ESBLs)和AmpCβ-内酰胺酶的存在情况及流行率。采用标准纸片扩散法测定对不同抗生素的耐药性。通过联合纸片法确定β-内酰胺酶表型。对ESBLs和AmpC阳性分离株使用聚合酶链反应(PCR)来确定blaCTX-M和blaCMY基因。在75株肺炎克雷伯菌分离株中,31株(41.3%)产生ESBLs,11株(14.6%)产生AmpCβ-内酰胺酶,1株(1.3%)对亚胺培南耐药,可能是在表型检测中产生了金属β-内酰胺酶。在一株分离株中检测到同时产生ESBLs和AmpCβ-内酰胺酶以及blaCTX-M和blaCMY基因的共存情况。分离株中blaCTX-M和blaCMY的流行率分别为20%和2.6%。当感染中出现超产β-内酰胺酶的生物体时,β-内酰胺治疗可能会失败。对于由这些病原体引起的感染的治疗,共表达多种类型β-内酰胺酶的分离株的出现可能会导致严重问题。